Epidemiology of chronic renal disease in the Galician population: Results of the pilot Spanish EPIRCE study

Otero, Alfonso; Gayoso, P; García, Fernando; Francisco, Angel Lm De

doi:10.1111/j.1523-1755.2005.09904.x

Cited by 106 publications

(72 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In Europe, Hallan and colleagues 32 (2006) reported an adult population prevalence of 4.7% for CKD based on a single eGFR estimate, and a similar prevalence has been reported in Italy, Switzerland, Spain and Iceland. [33][34][35][36] In the UK, the only population-based survey estimate of CKD prevalence comes from a cohort of men aged 60-79 years and tested in 1998-2000. Wannamethee and colleagues 37 estimated the prevalence of CKD to be 15.7%.…”

Section: Emerging 'Epidemic': Epidemiology Of Chronic Kidney Diseasementioning

confidence: 99%

See 1 more Smart Citation

Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis

Black

Sharma²,

Scotland³

et al. 2010

Health Technol Assess

175

144

View full text Add to dashboard Cite

How to obtain copies of this and other HTA programme reports An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address. Paying by credit cardYou can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume. How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment programmeT he Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects...

show abstract

Section: Emerging 'Epidemic': Epidemiology Of Chronic Kidney Diseasementioning

confidence: 99%

“…35 The Birmingham Rehabilitation Uptake Maximisation Study (BRUM). Homebased compared with hospitalbased cardiac rehabilitation in a multiethnic population: cost-effectiveness and patient adherence.…”

Section: Databases Searchedmentioning

confidence: 99%

Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis

Black

Sharma²,

Scotland³

et al. 2010

Health Technol Assess

175

144

View full text Add to dashboard Cite

show abstract

“…Les modèles de multi-morbidité des malades des pays africains diffèrent de ceux des pays développés par le fait de l'accessibilité géographique et financière des soins [17]. Par exemple en comparaison avec certains pays à haut revenu, plusieurs travaux montrent que les prévalences de maladies rénales chroniques (MRC) atteignent ou dépassent dix pourcent dans les pays riches tels qu'États-Unis [18], Espagne [19], Japon [20], Canada [21], Italie [22] et Norvège [23]. Comme dans les pays riches, cette prévalence de MRC à Kinshasa est de 12,4 % [24].…”

Section: éTat De Lieux Des Maladies Chroniques En Afrique Subsaharienunclassified

Fardeau des maladies chroniques en Afrique subsaharienne : plaidoyer pour une mise en place des soins palliatifs et d’accompagnement en fin de vie en République démocratique du Congo

Lofandjola

Sumaili

Pétermans

2017

Ethics, Medicine and Public Health

View full text Add to dashboard Cite

Fardeau des maladies chroniques enSummary The burden of chronic diseases (especially non-communicable) is the world's major public health challenge. The combination of erratic economic development, inadequate health systems, lacking diagnostic and therapeutic capabilities, is provoking in many resource-limited countries including the Democratic Republic of Congo (DRC) an inability to manage the current extent of these diseases. Added to this is the widespread poverty and environmental challenges. In this context, the need for palliative care services for terminally ill patients is enormous and undeniable. Training and information for policy makers, caregivers and families are needed in the health transition. The palliative care could be the solution to a support with dignity, improving chronic patients' quality of life. This article presents and analyzes the extent of these chronic diseases and seeks to make a place to implement this care in medical practice in Kinshasa. Three main reasons (epidemiological transition, lack of training of caregivers of palliative approaches and priority by policy makers of these chronic diseases) should motivate all stakeholders (partners, political, caregivers and families) to implement these treatments in medical practices and to these diseases are not neglected in Sub-saharan Africa.

show abstract

“…The prevalence of CKD at stage 3 or higher [17,18] is 6.8% of the general population in Spain. [18] Anemia is a common complication of CKD, and the risk of developing anemia is higher in individuals with low GFR.…”

Section: Discussionmentioning

confidence: 99%

Anemia Development and Cardiovascular Risk Management in Nonanemic Stage 3 Chronic Kidney Disease

et al. 2009

View full text Add to dashboard Cite

Background/Aim. There is little information on the development of anemia in the early stages of chronic kidney disease. The aim of this study was to analyze the onset of renal anemia in a cohort of initially nonanemic chronic kidney disease patients followed up in nephrology clinics. Methods. This epidemiological, prospective, three-year, multicenter study enrolled patients aged 18-78 years with stage 3 chronic kidney disease without anemia. Interim analysis was performed on the data collected during the first 12 months. Results. The study included 432 patients, average age 63.6 years (range 22-78 years, 70% male). The main etiologies of chronic kidney disease were glomerular (11.6%), interstitial (10.4%), vascular (29.4%), and diabetic (16.9%). The percentages of patients with comorbidities were 33.8% diabetes (2.5% type 1), 69% dyslipidemia, and 93% hypertension. During the first year, 12.4% of patients developed anemia. The chronic kidney disease progression rate was low: proteinuria was 0.46 ± 0.8 g/24 h at one year versus 0.67 ± 1.0 g/24 h at baseline. Diabetic patients showed a greater prevalence of previous cardiovascular events (50.0% vs. 24.5%) and worse control of some modifiable cardiovascular risk factors: smoking (13.4% vs. 8.6%), obesity (BMI > 30 kg/m 2 , 33.6% vs. 25.3%), target blood pressure (<130/80 mmHg, 21.0% vs. 27.9%), and proteinuria (0.8 ± 1.1 vs. 0.6 ± 0.9 g/day). Conclusions. After one year, 12.4% of patients developed anemia. Diabetic patients had a higher cardiovascular risk and limited blood pressure control. The overall control of cardiovascular risk was unsatisfactory.

show abstract

Epidemiology of chronic renal disease in the Galician population: Results of the pilot Spanish EPIRCE study

Cited by 106 publications

References 8 publications

Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis

Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis

Fardeau des maladies chroniques en Afrique subsaharienne : plaidoyer pour une mise en place des soins palliatifs et d’accompagnement en fin de vie en République démocratique du Congo

Anemia Development and Cardiovascular Risk Management in Nonanemic Stage 3 Chronic Kidney Disease

Contact Info

Product

Resources

About